The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]
It requires a comprehensive, sustainable approach that considers your individual body, lifestyle, and health needs
Each vial is third-party verified at 99%+ HPLC purity and lot-tracked with a certificate of analysis
Real Care
Understanding why these changes occur, what to expect, and when symptoms require medical attention helps patients manage treatment effectively whilst maintaining therapeutic benefits
doi:10.1136/bmj-2022-074068 Mller TD, Finan B, Bloom SR, et al